article thumbnail

Sulbactam-Durlobactam for Bacterial Pneumonia Gets FDA Approval

Drug Topics

The antibiotic, marketed as Xacduro, is indicated for hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by susceptible strains of bacteria called Acinetobacter baumannii.

Hospitals 468
article thumbnail

FDA: Updated Guidance to Increase Ibuprofen Supply for Children

Drug Topics

The FDA has updated its compounding guidelines for licensed pharmacies, hospitals, and health systems.

FDA 247
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Could FDA recommend new antibiotic for hospital-acquired pneumonia?

European Pharmaceutical Review

A Phase III trial has found that the novel combination antibiotic sulbactam-durlobactam prevents at least as many fatalities of hospital-acquired pneumonia as colistin, the best currently approved treatment. However, with these positive trial results, there is potential for the FDA to approve the new antibiotic.

Hospitals 105
article thumbnail

STAT+: FDA is still struggling to inspect clinical research sites, watchdog finds

STAT

Food and Drug Administration’s oversight of clinical research in hospitals and clinics has fallen considerably in recent years, due to disruptions caused by the Covid pandemic and challenges finding and keeping investigators, according to a new report by the U.S. By comparison, the FDA inspected 976 clinical study sites in 2017.

FDA 127
article thumbnail

STAT+: FDA seeks to regulate lab-developed tests, closing the ‘Theranos loophole’

STAT

Lawmakers came close last year to passing a bill that would have given the FDA this authority, but it was ultimately rejected by Republicans who sympathized with the labs in academic medical centers and hospitals that opposed the provision.

FDA 142
article thumbnail

STAT+: FDA inspection underscores problem at major U.S. compounder behind hospital drug recalls

STAT

recently recalled a slew of injectable medicines used by hospitals over concerns about possible side effects and a newly released regulatory report underscores the extent of the problem. One of the largest compound pharmacy operations in the U.S. facility run by Central Admixture Pharmacy Services.

article thumbnail

STAT+: FDA panel unanimously endorses Eisai’s Alzheimer’s drug

STAT

The group voted 6-0 that an 1,800-patient study of Leqembi confirmed its benefits for patients in the early stages of Alzheimer’s, recommending the FDA widen the drug’s limited approval. The agency, which is not required to follow the suggestions of its advisers, is expected to make a final decision on Leqembi by July 6.

FDA 144